Business context and reporting period
Filing identity: The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended September 30, 2016—not a filing identified as Talphera, Inc. Verify the issuer before relying on this summary. AcelRx develops acute-pain therapies; its lead candidates were ARX-04 and Zalviso. Figures below are in U.S. dollars unless noted.
Financial results and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $3.4m | $15.4m | $10.9m | $17.5m |
| Operating loss | $8.0m | Operating income $7.1m | $24.8m | $12.4m |
| Net loss (income) | $11.4m loss | $5.1m income | $33.5m loss | $13.9m loss |
| Operating cash flow | Not stated for quarter | $19.1m used | $26.9m used |
Revenue fell mainly because the prior-year periods included substantial collaboration-license revenue ($13.2m in Q3 2015 and nine months 2015), while 2016 collaboration revenue was $1.6m and $4.7m, respectively. Q3 2016 included $1.8m of Department of Defense (DoD) contract revenue; nine-month DoD revenue was $6.2m. Zalviso product sales to Grünenthal were $1.4m in Q3 and $4.3m year to date. Cost of goods sold was $2.6m and $9.2m, respectively; the filing does not present a standalone gross-margin percentage.
At September 30, 2016, cash and cash equivalents were $92.5m, with no short-term investments, versus cash and investments of $113.5m at December 31, 2015. Current assets were $96.9m and current liabilities $15.5m. Total liabilities were $102.7m and stockholders’ equity $3.3m, down from $33.1m at year-end 2015; accumulated deficit was $236.7m. Hercules debt was $21.3m outstanding (balance-sheet current and long-term portions totaled $21.3m). The separate liability for monetized future royalties was $70.5m, including $6.9m of non-cash interest expense for the first nine months; the company estimated an approximately 14% effective annual rate.
Material changes versus prior comparable periods
- Nine-month net loss increased from $13.9m to $33.5m, while operating cash use declined from $26.9m to $19.1m. The comparisons were affected by prior-year collaboration-license revenue and the 2015 $61.2m net proceeds from the royalty monetization.
- Nine-month R&D expense declined 21% to $15.1m, principally from lower overhead and Zalviso spending; ARX-04 spending increased. G&A rose 13% to $11.5m, including ARX-04 market research costs.
- On September 30, AcelRx amended its Hercules facility, extending the interest-only period through April 1, 2017 and reducing lender warrant exercise prices from $3.88 to $3.07. Debt maturity remained in October 2017 absent a further amendment.
- The September 2016 Grünenthal amendment revised supply configurations and pricing, reduced sales-contingent milestone payments by $5.5m, added $0.7m of development services, and included a binding product forecast of approximately $3.7m.
Outlook, commentary and key risks
- Management anticipated submitting the ARX-04 U.S. NDA by the end of 2016 and a European hybrid application in the first half of 2017. ARX-04 Phase 3 studies were reported as completed with positive results; regulatory review and any additional study requirements remained uncertain.
- Zalviso’s U.S. NDA had received a 2014 Complete Response Letter. The FDA-requested IAP312 study began in September 2016, with enrollment and treatment expected to continue through mid-2017; successful results would not guarantee approval or NDA resubmission acceptance.
- Management estimated existing capital would fund operations through at least the end of 2017, but said additional capital would be needed to sustain operations until revenues could do so. The company continued to incur losses and expected negative operating cash flows.
- Zalviso was commercially available in Germany, France and the U.K.; pilot programs were underway in several other European countries. Management expected 2016 European royalty revenue to be minimal. Cartridge deliveries from Patheon were behind Grünenthal’s schedule, potentially affecting sales and launches. Revised controller software and manufacturing timelines also posed execution risks.
- The DoD contract provided up to $17m for ARX-04 development, subject to eligible costs and contract terms. The company also had a $40m ATM sales agreement but had sold no shares under it by quarter-end.
- Other material risks include regulatory delays or rejection, clinical-trial and manufacturing setbacks, opioid safety and commercial acceptance, dependence on Grünenthal and contract manufacturers, restricted future royalty cash flows following the PDL transaction, and potential dilution or inability to raise capital.
Important facts for investors to verify
- Confirm the issuer: this source is AcelRx Pharmaceuticals, Inc., despite the request naming Talphera, Inc.
- Check subsequent FDA actions and actual timing/results for the ARX-04 NDA and Zalviso IAP312 study; the filing’s dates are forward-looking expectations.
- Verify Patheon cartridge delivery status, revised controller rollout, and Grünenthal launch and sales performance.
- Review cash burn, financing activity, Hercules repayment terms, and the assumptions behind management’s runway estimate through end-2017.
- Assess the PDL royalty-monetization cap, future royalty allocation, and resulting non-cash interest expense against actual product sales and milestone receipts.